We then determined the half maximal inhibitory concentration (IC50) value by CCK-8 assay, and we found that after knockdown of FBXW11, the IC50 value of olaparib was increased compared with the control group in all three ovarian cancer cell lines (Figs. 1F and S1). This evidence concerns the gene FBXW11 and ovarian carcinoma.